(Q35169077)

6 August 2017

title

Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis (English)

1 reference

6 August 2017

Antony T H Lin

1

1 reference

6 August 2017

Philip J Clements

series ordinal

2

1 reference

6 August 2017

Daniel E Furst

series ordinal

3

1 reference

6 August 2017

publication date

1 May 2003

1 reference

Rheumatic Diseases Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

29

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

409-426

1 reference

Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Clinical exercise testing

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Rational therapy in the treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Medical therapy of pulmonary hypertension. The prostacyclins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Clinical course of patients with scleroderma renal crisis treated with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Use of captopril as early therapy for renal scleroderma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Long-term outcomes of scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Stem cell transplantation for autoimmune disease: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Human antitransforming growth factor beta(2) monoclonal antibody--a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Cyclofenil treatment of scleroderma--a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Scleroderma and related disorders: therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Drug treatment of scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

Novel therapy in the treatment of scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2803%2900026-7

7 January 2021

10.1016/S0889-857X(03)00026-7

Identifiers

DOI

1 reference

6 August 2017

1 reference